首页> 外国专利> Identifying the preferential target antigens of antitumor T cells comprises transfecting autologous dendritic or B cells with a selection of mRNAs coding for tumor-associated antigens

Identifying the preferential target antigens of antitumor T cells comprises transfecting autologous dendritic or B cells with a selection of mRNAs coding for tumor-associated antigens

机译:鉴定抗肿瘤T细胞的优先靶抗原包括用编码肿瘤相关抗原的mRNA选择转染自体树突状或B细胞

摘要

Identifying the preferential target antigens of antitumor T cells comprises isolating T cells from the blood of a tumor patient, transfecting autologous dendritic or B cells with a selection of mRNAs coding for tumor-associated antigens, contacting the T cells with the dendritic or B cells, and identifying the antigens recognized by the T cells. Independent claims are also included for: (1) identifying a tumor in a patient on the basis of an antigen expression pattern determined as above; (2) producing an individualized antitumor vaccine by identifying tumor-associated antigens as above and formulating the antigens as a vaccine; (3) treating a tumor disease on the basis of an antigen expression pattern determined as above. ACTIVITY : Cytostatic. MECHANISM OF ACTION : Vaccine.
机译:鉴定抗肿瘤T细胞的优先靶抗原包括从肿瘤患者的血液中分离T细胞,用编码肿瘤相关抗原的mRNA选择转染自体树突或B细胞,使T细胞与树突或B细胞接触,并鉴定T细胞识别的抗原。还包括以下独立权利要求:(1)基于如上确定的抗原表达模式在患者中鉴定肿瘤; (2)通过如上所述鉴定与肿瘤相关的抗原并将所述抗原配制为疫苗来生产个体化的抗肿瘤疫苗; (3)根据上述确定的抗原表达模式治疗肿瘤疾病。活动:细胞静息。作用机理:疫苗。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号